Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
687.80M | 673.30M | 820.00M | 744.60M | 714.80M | Gross Profit |
381.30M | 379.70M | 450.00M | 364.30M | 373.30M | EBIT |
-396.20M | 4.20M | 74.00M | 8.90M | -46.10M | EBITDA |
-345.60M | 50.60M | 77.80M | 8.90M | -2.00M | Net Income Common Stockholders |
-392.10M | -61.80M | 50.50M | 6.30M | -27.20M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
107.70M | 87.70M | 127.70M | 118.50M | 111.50M | Total Assets |
1.15B | 1.69B | 1.79B | 1.59B | 1.67B | Total Debt |
170.20M | 209.10M | 280.00M | 187.50M | 248.80M | Net Debt |
62.50M | 121.40M | 152.30M | 69.00M | 137.30M | Total Liabilities |
325.70M | 456.10M | 495.70M | 330.70M | 416.30M | Stockholders Equity |
828.50M | 1.24B | 1.29B | 1.26B | 1.26B |
Cash Flow | Free Cash Flow | |||
82.90M | 14.60M | 71.60M | 66.30M | -22.70M | Operating Cash Flow |
100.70M | 32.40M | 90.90M | 87.30M | -2.50M | Investing Cash Flow |
-27.50M | 21.60M | -135.40M | -21.00M | -24.20M | Financing Cash Flow |
-49.10M | -94.20M | 56.70M | -55.30M | -70.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $611.75M | ― | -18.38% | ― | 20.37% | 34.10% | |
55 Neutral | $534.87M | ― | -10.34% | ― | 37.65% | -77.01% | |
53 Neutral | $592.73M | ― | -37.28% | ― | 24.51% | 47.32% | |
52 Neutral | $553.73M | ― | -22.87% | ― | 7.08% | 20.45% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
50 Neutral | $568.14M | 45.80 | -37.42% | ― | -2.54% | -546.91% | |
49 Neutral | $627.43M | ― | -20.86% | ― | 11.89% | 79.18% |
On April 18, 2025, Avanos Medical announced the departure of Michael C. Greiner, who had served as Interim CEO and previously as CFO and Chief Transformation Officer. Greiner’s exit follows the appointment of Dave Pacitti as CEO on April 14, 2025. Greiner will receive a severance package, including a $2.1 million payment, prorated bonus, and consulting fees. Additionally, Jason M. Pickett has been appointed as Interim CFO and Treasurer, effective April 14, 2025, following Warren J. Machan’s transition to a consulting role. These leadership changes indicate a strategic shift within Avanos Medical, potentially impacting its operational focus and stakeholder relations.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score reflects a mix of moderate financial performance and weak technical indicators. The company’s net losses and negative valuation metrics are significant concerns. However, the recent appointment of a new CEO and strategic initiatives may offer potential for future growth. Current challenges in operational efficiency and a negative market sentiment keep the score on the lower side.
To see Spark’s full report on AVNS stock, click here.
On March 17, 2025, Avanos Medical announced the appointment of David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti, who previously held leadership roles at Siemens Healthineers and Abbott Vascular, brings extensive industry expertise and a strategic vision to the company. His appointment is expected to drive Avanos’s next phase of growth and success, with a focus on delivering breakthrough medical device solutions and enhancing long-term value for stakeholders.